Tammy Russo
Psychiatric/Mental Health · Niskayuna, NYNPI 1093976003
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $387,594 of the $568,227 with a category attached, or 68.2%. 21 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 44.0% of the total. 2025 is the largest year on record at $253,252, 9.9 times the $25,564 reported in 2021. Among psychiatric/mental health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,296 payments — averaging $438.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$250K
- Alkermes, Inc.$128K
- AbbVie$93K
- Teva Pharmaceuticals USA, Inc.$36K
- Supernus Pharmaceuticals, Inc.$19K
- Axsome Therapeutics, Inc.$13K
- plus $29K from 15 others
What the payments were for
- Consulting fees$26,4365%
- Speaking & faculty fees$387,59468%
- Travel & lodging$124,88322%
- Food & beverage$28,8525%
- Education$4620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 343 | $250,201 |
| Alkermes, Inc. | 201 | $127,769 |
| AbbVie(2 entities) | 247 | $93,189 |
| Teva Pharmaceuticals USA, Inc. | 93 | $36,135 |
| Supernus Pharmaceuticals, Inc. | 82 | $18,817 |
| Axsome Therapeutics, Inc. | 47 | $12,934 |
| Neurocrine Biosciences, Inc. | 50 | $12,757 |
| E.r. Squibb & Sons, L.L.C. | 18 | $12,052 |
| Johnson & Johnson | 53 | $1,037 |
| Sunovion Pharmaceuticals Inc. | 24 | $670 |
| Corium, LLC | 38 | $589 |
| Otsuka America Pharmaceutical, Inc. | 19 | $552 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $464 |
| Lundbeck LLC | 12 | $257 |
| Idorsia Pharmaceuticals US Inc | 16 | $255 |
| Ironshore Pharmaceuticals Inc. | 10 | $198 |
| Vanda Pharmaceuticals Inc. | 9 | $172 |
| Harmony Biosciences LLC | 3 | $121 |
| Avanir Pharmaceuticals, Inc. | 2 | $29 |
| Alfasigma USA, Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$568,227 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 14 | $100,855 |
| VraylarCariprazine Hcl | 66 | $100,410 |
| CaplytaLumateperone Tosylate | 27 | $57,059 |
| RexultiBrexpiprazole | 14 | $20,098 |
| Adderall XrDextroamphetamine/Amphetamine | 11 | $4,519 |
| VascepaIcosapent Ethyl | 11 | $2,226 |
| Fluvoxamine Maleate | 60 | $1,998 |
| Divalproex Sodium ErDivalproex Sodium | 14 | $945 |
| Bupropion XlBupropion Hcl | 30 | $706 |
| Quetiapine Fumarate | 29 | $685 |
| Ziprasidone Hcl | 24 | $504 |
| Clonazepam | 27 | $467 |
| Aripiprazole | 21 | $433 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 23 | $429 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 17 | $393 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $36,135 | $100,85514 claims |
| AbbVieVraylar | $93,189 | $100,41066 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $250,201 | $57,05927 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $552 | $20,09814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Other psychiatric/mental health in Niskayuna
- Daniel BreeyearNiskayuna$149K
- Carrie EdickSchenectady$484K
- Eric SpronzCentereach$448K
- Terry Jo Brooks-DevlinTonawanda$176K
- Kevin SiewersStaten Island$155K
- Elijah StevensBinghamton$131K
- Kayanna JonasFar Rockaway$93K
- Alexis CrisafiFishkill$70K
- Vera ImperialeAlbany$69K
- Matthew SharpePenfield$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.